Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7274" target="_blank" >RIV/00064203:_____/11:7274 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/11:7274

Result on the web

<a href="http://www.ncbi.nlm.nih.gov/pubmed/21948298" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/21948298</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)

Original language description

Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) sub-types requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize over-treatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% +/- 3% versus 80% +/- 6%, p(logrank)0.047, EFS 84% +/- 4% versus 59% +/- 7%, p(logrank)0.001, and CIR 14% +/- 4% versus 34% +/- 7%, p((gray)) 0.006. These differences were not seen for inv(16) (n = 43 and 46, resp

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

118

Issue of the periodical within the volume

20

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

5409-5415

UT code for WoS article

000297265400010

EID of the result in the Scopus database

—